Equities

Innovotech Inc

IOT:CVE

Innovotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.10
  • Today's Change0.00 / 0.00%
  • Shares traded6.00k
  • 1 Year change-9.09%
  • Beta0.8944
Data delayed at least 15 minutes, as of Apr 30 2024 17:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Innovotech Inc. is a Canada-based biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products.

  • Revenue in CAD (TTM)1.18m
  • Net income in CAD-157.59k
  • Incorporated2006
  • Employees16.00
  • Location
    Innovotech Inc2011 94 St NW Suite 101EDMONTON T6N 1H1CanadaCAN
  • Phone+1 (780) 448-0585
  • Fax+1 (780) 424-0941
  • Websitehttps://innovotech.ca/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
IOT:CVE since
announced
Transaction
value
Nou Life Sciences IncAnnounced18 Aug 202318 Aug 2023Announced11.11%--
Data delayed at least 15 minutes, as of Apr 30 2024 17:41 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Entourage Health Corp39.46m-116.92m3.07m251.00------0.0778-0.3807-0.38070.1285-0.42150.49541.798.08---146.79-46.15---74.686.12-53.10-296.29-214.310.0992-1.136.15---3.2694.98-56.01---13.82--
Therma Bright Inc25.80k-2.88m3.16m----1.72--122.45-0.0115-0.01150.00010.00580.00760.00230.115---84.40-220.66-165.23-444.5798.45---11,152.48-10,853.160.0447-184.520.0411---82.8611.1335.93--40.15--
Quest PharmaTech Inc0.00-22.26m3.38m0.00--0.0511-----0.1319-0.13190.000.39130.00-------28.4623.29-28.8627.25-----------0.05550.0149------91.38------
Hemostemix Inc0.00-2.50m3.48m-----------0.0303-0.03030.00-0.08460.00-------642.29-599.98---------------3.99--------52.21------
Eve & Co Inc7.77m-5.92m3.76m--------0.484-0.2055-0.20550.26980.7330.15190.74938.73---11.58---24.24---3.10---76.22--0.062-5.050.4892--2.94---71.97------
Innovotech Inc1.18m-157.59k3.90m16.00--4.19--3.30-0.004-0.0040.03040.02390.96966.625.51---12.922.90-15.523.5668.6371.56-13.332.192.82--0.00--5.057.42-15.43--35.69--
Appili Therapeutics Inc1.15m-5.34m4.24m8.00------3.69-0.044-0.0440.0095-0.08110.5047--2.12---234.31-117.41---173.66-----464.23-3,037.15---5.32-----75.97--63.20---43.04--
Data as of Apr 30 2024. Currency figures normalised to Innovotech Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.